SWATI AG has been set up in the canton of Zug in 2019, with a vision to engage with European innovation for the world. To facilitate as a golden triangle between credible Indian Manufacturing, European Innovation & Global markets.
Our business has two main pillars. The first is, world class manufacturing spread between Indian cost-effective high credibility platform and cutting edge technology & research out of Germany. The second pillar being intelligent business models diversifying risks between large volume key pharmaceutical ingredients to strategic product portfolio of steroids and high potency hormones, to repurposing of drugs which give access to huge global markets and growth potentials. With its fully backward integrated platforms of starting material & key intermediates to fully forward integrated to finished dosages, clinical studies and brand selling, we have the perfect balance of risk mitigation and high growth.
Our prime focus are the highly regulated markets like EU, USA, Japan as well as hugely rewarding large complex markets like China, Russia, Brazil. These markets give a high adrenaline boost in profit potential. Our facilities and compliances are in line with US FDA, EDQM & Japanese PMDA, which covers almost all global market compliances.
The core therapeutic areas are Urology & Gynaecology, where besides having control over the key ingredients of the finished dosage we also have strong control over the curriculum prepared by us, for the professors who teach the doctors on diagnosis of debilitating diseases like interstitial Cystitis and other rare or orphan diseases. We also have very firm and strategic plans in unserved diseases like Diabetic Nephropathy, where currently patients have no medicine to manage early stage disease inflammation.
The company’s flagship molecule is Pentosan Polysulphate sodium knows as PPS. The company is currently using PPS for treating Interstitial cystitis (I.C)/Bladder Pain Syndrome (BPS). BPS is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area, combined with lower urinary tract symptoms which have lasted for more than 6 weeks, without having an infection or other clear causes. Hugely untapped, under served and poorly understood by all stakeholders. The parent company SSPL is the first company in the world to launch a generic version of PPS for neglected disease for human use. The original brand product ‘Elmiron’ went off patent in Jan 2010 and till today no one has been able to develop and equivalent generic. Swati expects to be the first Generic in USA by 2022-23, offering an opportunity to profit while benefiting the patients by bringing down the high medicine prices, which make many patients to skip medicines leading to suicidal tendencies. The group proudly boasts of being the first company in the world to not only launch generic in more than 5 countries, but also educate the stakeholders and open up new blue ocean markets – truly creating value. This also affirms and guarantees that Swati’s launch in USA without a doubt will be a success, once through with regulatory processes.
It is extending this subject skill to other indications by repurposing for high unmet need segments of Diabetic nephropathy, Thrombosis, Urology, Gynaecology & osteoarthritis. Truly a rising star… Globally.